For example, in the KEYNOTE‐189 clinical trial, immunotherapy with pembrolizumab in combination with standard chemotherapy produced a survival benefit in all patients regardless of PD‐L1 expression, even among those with a PD‐L1 tumor proportion score less than 1%, which should indicate a small chance of benefit.81 The gene discussed is CD274; the disease is neoplasm.